Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest in this topic

  1. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients 2016-11-01
  2. 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads 2015-10-10
  3. BACE1 inhibitor drugs in clinical trials for Alzheimer's disease 2014-12-24

Studies

5 studies carry this tag.

Date range

2012 to 2016

Top journals

  • Alzheimer's research & therapy 1
  • Clinical pharmacology in drug development 1
  • Journal of medicinal chemistry 1
  • Molecules (Basel, Switzerland) 1
  • Science translational medicine 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Science translational medicine 2016-11-01 Tau biomarkers

    β-Amyloid (Aβ) peptides are thought to be critically involved in the etiology of Alzheimer's disease (AD).

  2. 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of medicinal chemistry 2015-10-10 Treatments

    1,4-Oxazines are presented, which show good in vitro inhibition in enzymatic and cellular BACE1 assays.

  3. BACE1 inhibitor drugs in clinical trials for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer's research & therapy 2014-12-24 Risk genes beyond APOE

    β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the β-secretase enzyme required for the production of the neurotoxic β-amyloid (Aβ) peptide that is widely considered to have a crucial early role in the etiology of Alzheimer's disease (AD).

  4. Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. Clinical pharmacology in drug development 2014-05-26 Biomarkers

    Modulating deposition of Aβ-containing plaques in the brain may be beneficial in treating Alzheimer's disease. β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors have been shown to reduce Aβ in plasma and CSF in healthy volunteers.

  5. From BACE1 inhibitor to multifunctionality of tryptoline and tryptamine triazole derivatives for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Molecules (Basel, Switzerland) 2012-07-10 Treatments

    Efforts to discover new drugs for Alzheimer's disease emphasizing multiple targets was conducted seeking to inhibit amyloid oligomer formation and to prevent radical formation.

All topic tags with their study counts